Search Results - "Zojwalla, N."

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391) by Palumbo, A, Stewart, A.K, Rajkumar, S.V, Masszi, T, Spicka, I, Oriol, A, Hájek, R, Rosiñol, L, Siegel, D, Mihaylov, G.G, Goranova-Marinova, V, Rajnics, P, Suvorov, A, Niesvizky, R, Jakubowiak, A, San-Miguel, J, Ludwig, H, Zojwalla, N, Tonda, M, Obreja, M, Moreau, P, Dimopoulos, M.A

Get full text

Superior Health-Related Quality of Life with Carfilzomib, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma (MM): Results From the ASPIRE Trial by Stewart, A.K, Dimopoulos, M.A, Masszi, T, Spicka, I, Oriol, A, Hájek, R, Rosiñol, L, Siegel, D.S, Niesvizky, R, Jakubowiak, A.J, San-Miguel, J.F, Ludwig, H, Rajkumar, S.V, Buchanan, J, Cocks, K, Yang, X, Xing, B, Zojwalla, N, Tonda, M, Moreau, P, Palumbo, A

Get full text

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma by Stewart, A. Keith, Rajkumar, S. Vincent, Dimopoulos, Meletios A, Masszi, Tamás, Špička, Ivan, Oriol, Albert, Hájek, Roman, Rosiñol, Laura, Siegel, David S, Mihaylov, Georgi G, Goranova-Marinova, Vesselina, Rajnics, Péter, Suvorov, Aleksandr, Niesvizky, Ruben, Jakubowiak, Andrzej J, San-Miguel, Jesus F, Ludwig, Heinz, Wang, Michael, Maisnar, Vladimír, Minarik, Jiri, Bensinger, William I, Mateos, Maria-Victoria, Ben-Yehuda, Dina, Kukreti, Vishal, Zojwalla, Naseem, Tonda, Margaret E, Yang, Xinqun, Xing, Biao, Moreau, Philippe, Palumbo, Antonio

“…In this study, the addition of carfilzomib to lenalidomide and dexamethasone improved response rates and overall survival among patients with relapsed multiple…”
Get full text

911PD - A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC by Jonasch, E., Plimack, E.R., Bauer, T., Merchan, J.R., Papadopoulos, K.P., McDermott, D.F., Michaelson, M.D., Appleman, L.J., Thamake, S., Zojwalla, N., Choueiri, T.K.

“…Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC). PT2977 is a potent and selective…”
Get full text

A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC by Jonasch, E., Plimack, E.R., Bauer, T., Merchan, J.R., Papadopoulos, K.P., McDermott, D.F., Michaelson, M.D., Appleman, L.J., Thamake, S., Zojwalla, N., Choueiri, T.K.

Get full text

911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC by Jonasch, E, Plimack, E R, Bauer, T, Merchan, J R, Papadopoulos, K P, McDermott, D F, Michaelson, M D, Appleman, L J, Thamake, S, Zojwalla, N, Choueiri, T K

“…Abstract Background Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC). PT2977 is a…”
Get full text

Regional and racial disparities in breast cancer-specific mortality by Grann, Victor, Troxel, Andrea B., Zojwalla, Naseem, Hershman, Dawn, Glied, Sherry A., Jacobson, Judith S.

“…Where and how one lives is associated with cancer survival. This study was designed to assess geographical region of residence, race/ethnicity, and clinical…”
Get full text

Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors by Schoffski, P., Adkins, D., Blay, J., Gil, T., Elias, A. D., Rutkowski, P., Pennock, G. K., Youssoufian, H., Zojwalla, N. J., Willey, R., Grebennik, D. O.

“…Abstract only…”
Get full text

Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC) by Abou-Alfa, G. K., Gansukh, B., Chou, J. F., Shia, J., Capanu, M., Kalin, M., Chen, H. X., Zojwalla, N. J., Katz, S., Reidy, D. L., Kelsen, D. P., Saltz, L.

“…Abstract only…”
Get full text

Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma by Anthony, L. B., Loehrer, P. J., Leong, S., Shah, M. H., Safran, H., Senzer, N. N., Zojwalla, N. J., Youssoufian, H.

“…Abstract only…”
Get full text

Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients by Zojwalla, N. J., Raftopoulos, H., Gralla, R. J.

“…Abstract only…”
Get full text

Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients by Zojwalla, N. J., Raftopoulos, H., Gralla, R. J.

“…Abstract only…”
Get full text

A phase I trial of E7974 administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies by Zojwalla, N. J., Takimoto, C. H., Lucarelli, A. G., Clark, R., Mita, A. C., Mita, M. M., Romero, O., Schuck, E. L., Krivelevich, I., Sweeney, C. J.

“…Abstract only 2543 Background: E7974 is a synthetic hemiasterlin analogue exhibiting binding to a and β tubulin. It induces disruption of spindle formation and…”
Get full text

A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies by Madajewicz, S., Zojwalla, N. J., Lucarelli, A. G., Hentschel, P., Giardelli, J., Schuck, E. L., Krivelevich, I., Wong, B. Y., Vogelzang, N. J., Sharma, S.

“…Abstract only 2550 Background: E7974 is a synthetic hemiasterlin analogue exhibiting binding to a and β tubulin. It induces disruption of spindle formation and…”
Get full text

Hormone receptor status and survival in a population‐based cohort of patients with breast carcinoma by Grann, Victor R., Troxel, Andrea B., Zojwalla, Naseem J., Jacobson, Judith S., Hershman, Dawn, Neugut, Alfred I.

“…BACKGROUND The objective of this study was to assess hormone receptor status as an independent predictor of survival in a population‐based cohort of women with…”
Get full text

Cixutumumab by Rowinsky, E.K., Schwartz, J.D., Zojwalla, N., Youssoufian, H., Fox, F., Pultar, P., Ludwig, D.L.

Get full text